Want to see ISPC full AI Analyst Report?
ISPC Stock Chart & Stats
$0.31
-$0.03(-1.03%)
At close: 4:00 PM EST
$0.31
-$0.03(-1.03%)
Day’s Range― - ―
52-Week Range$2.39 - $127.20
Previous CloseN/A
Volume25.67K
Average Volume (3M)8.88M
Market Cap
$3.79M
Enterprise Value-$2.21M
Total Cash (Recent Filing)$2.82M
Total Debt (Recent Filing)$254.99K
Price to Earnings (P/E)―
Beta1.34
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,437,157
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap-0.58
Enterprise Value/Revenue-2.15
Enterprise Value/Gross Profit7.26
Enterprise Value/Ebitda0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Marketplace Business ModelA technology-enabled marketplace linking buyers and a broad supplier network creates structural value: service fees on fulfilled orders, scalable sourcing, and potential network effects. Durable recurring transaction flow supports long-term unit economics if volume recovers and supplier coverage expands.
Streamlined Global Shipping & SourcingDirect-shipment logistics and expanded European sourcing materially raise operational competitiveness: faster deliveries, lower costs, and broader access to rare specimens. These structural improvements increase fulfillment reliability and market reach across domestic and international research customers.
Low Financial LeverageVery low debt reduces near-term interest burden and gives balance-sheet flexibility to raise equity or negotiate financing. For a cash-burning growth-stage marketplace, limited leverage lowers default risk and preserves capacity to fund operations via non-debt sources if capital markets access is maintained.
Bears Say
Steep Revenue Decline & Weak MarginsA near-halving of TTM revenue and deeply negative margins indicate structural demand or execution challenges. Sustained top-line erosion undermines scale benefits, prevents fixed-cost absorption, and makes it hard to achieve durable profitability without a clear, sustained recovery in orders or pricing.
Persistent Cash BurnConsistent negative operating and free cash flow forces reliance on external financing. Over months, ongoing cash burn raises dilution and financing risk, constrains reinvestment in product and sales, and makes the business dependent on successful capital raises or rapid margin improvements to sustain operations.
Nasdaq Equity Noncompliance And Listing RiskFailing minimum equity standards creates tangible listing risk that can curtail public capital access and increase cost of capital. Management must restore equity quickly or face delisting, a structural setback that would hinder long-term funding, partnerships, and institutional investor participation.
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
iSpecimen lowest stock price was $2.39 and its highest was $127.20 in the past 12 months.
What is iSpecimen’s market cap?
iSpecimen’s market cap is $3.79M.
When is iSpecimen’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iSpecimen’s earnings last quarter?
Currently, no data Available
Is iSpecimen overvalued?
According to Wall Street analysts iSpecimen’s price is currently Overvalued.
Does iSpecimen pay dividends?
iSpecimen does not currently pay dividends.
What is iSpecimen’s EPS estimate?
iSpecimen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iSpecimen have?
iSpecimen has 1,437,157 shares outstanding.
What happened to iSpecimen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of iSpecimen?
Currently, no hedge funds are holding shares in ISPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
iSpecimen
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Technical Analysis
―
Intelligent Bio Solutions
―
BioNexus Gene Lab Corp
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
4.42% Mutual Funds
― Other Institutional Investors
95.58% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---